ACB stock forecast updates indicate that debt restructuring efforts have improved balance sheet health, potentially enhancing investor confidence and lifting valuations past CAD 1.12 in the mid-term. Revenues are expected to be $52.11 million, up 10% from a year ago. While ACB stock is likely not out of danger just yet, reclassification and movement towards eventual legalization in America should help the company and its shareholders moving forward. Aurora Cannabis has a consensus “Buy” rating, with the average 12-month price target at approximately C$7.00 per share. The most recent ACB stock forecast notes sector growth rate projections at 8% annually. If Aurora Cannabis aligns its strategy effectively, market pricing could inch toward CAD 1.15 before year-end.
